Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
Copyright ©ERS 2017..
Studies reporting the effects of modern strategies with pulmonary arterial hypertension (PAH)-targeted therapies in sarcoidosis-associated pulmonary hypertension (S-APH) are limited.Clinical and haemodynamic data from newly diagnosed patients with severe S-APH (mean pulmonary artery pressure (mPAP) >35 mmHg or mPAP 25-35 mmHg with cardiac index <2.5 L·min-1·m-2) were collected from the French Pulmonary Hypertension Registry between 2004 and 2015.Data from 126 patients with severe S-APH were analysed (mean±sd age 57.5±11.6 years, 74% radiological stage IV). 97 patients (77%) received PAH-targeted therapy and immunosuppressive therapy was initiated or escalated in 33 patients at the time of pulmonary hypertension diagnosis. Four months after PAH-targeted therapy initiation, mean±sd pulmonary vascular resistance decreased from 9.7±4.4 to 6.9±3.0 Wood units (p<0.001), without significant improvement in exercise capacity. Among the 11 patients treated only with immunosuppressive therapy, a haemodynamic improvement was observed in four patients, including two with compressive lymph nodes. After a median follow-up of 28 months, 39 patients needed PAH-targeted therapy escalation, nine underwent lung transplantation and 42 had died. Survival at 1, 3 and 5 years was 93%, 74% and 55%, respectively.PAH-targeted therapy improved short-term pulmonary haemodynamics in severe S-APH without change in exercise capacity. Immunosuppressive therapy improved haemodynamics in selected patients. Pulmonary hypertension in sarcoidosis remains associated with a poor prognosis.
| Errataetall: |
CommentIn: Eur Respir J. 2017 Oct 19;50(4):. - PMID 29051277 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
The European respiratory journal - 50(2017), 4 vom: 02. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boucly, Athénaïs [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.06.2018 Date Revised 10.12.2019 published: Electronic-Print CommentIn: Eur Respir J. 2017 Oct 19;50(4):. - PMID 29051277 Citation Status MEDLINE |
|---|
| doi: |
10.1183/13993003.00465-2017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277197201 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277197201 | ||
| 003 | DE-627 | ||
| 005 | 20231225013654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/13993003.00465-2017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0924.xml |
| 035 | |a (DE-627)NLM277197201 | ||
| 035 | |a (NLM)29051269 | ||
| 035 | |a (PII)1700465 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boucly, Athénaïs |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2018 | ||
| 500 | |a Date Revised 10.12.2019 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a CommentIn: Eur Respir J. 2017 Oct 19;50(4):. - PMID 29051277 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright ©ERS 2017. | ||
| 520 | |a Studies reporting the effects of modern strategies with pulmonary arterial hypertension (PAH)-targeted therapies in sarcoidosis-associated pulmonary hypertension (S-APH) are limited.Clinical and haemodynamic data from newly diagnosed patients with severe S-APH (mean pulmonary artery pressure (mPAP) >35 mmHg or mPAP 25-35 mmHg with cardiac index <2.5 L·min-1·m-2) were collected from the French Pulmonary Hypertension Registry between 2004 and 2015.Data from 126 patients with severe S-APH were analysed (mean±sd age 57.5±11.6 years, 74% radiological stage IV). 97 patients (77%) received PAH-targeted therapy and immunosuppressive therapy was initiated or escalated in 33 patients at the time of pulmonary hypertension diagnosis. Four months after PAH-targeted therapy initiation, mean±sd pulmonary vascular resistance decreased from 9.7±4.4 to 6.9±3.0 Wood units (p<0.001), without significant improvement in exercise capacity. Among the 11 patients treated only with immunosuppressive therapy, a haemodynamic improvement was observed in four patients, including two with compressive lymph nodes. After a median follow-up of 28 months, 39 patients needed PAH-targeted therapy escalation, nine underwent lung transplantation and 42 had died. Survival at 1, 3 and 5 years was 93%, 74% and 55%, respectively.PAH-targeted therapy improved short-term pulmonary haemodynamics in severe S-APH without change in exercise capacity. Immunosuppressive therapy improved haemodynamics in selected patients. Pulmonary hypertension in sarcoidosis remains associated with a poor prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Cottin, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Nunes, Hilario |e verfasserin |4 aut | |
| 700 | 1 | |a Jaïs, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Tazi, Abdelatif |e verfasserin |4 aut | |
| 700 | 1 | |a Prévôt, Grégoire |e verfasserin |4 aut | |
| 700 | 1 | |a Reynaud-Gaubert, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Dromer, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Viacroze, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Horeau-Langlard, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Pison, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Bergot, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Traclet, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Weatherald, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Simonneau, Gérald |e verfasserin |4 aut | |
| 700 | 1 | |a Valeyre, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Montani, David |e verfasserin |4 aut | |
| 700 | 1 | |a Humbert, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Sitbon, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Savale, Laurent |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d 1989 |g 50(2017), 4 vom: 02. Okt. |w (DE-627)NLM012664782 |x 0903-1936 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2017 |g number:4 |g day:02 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/13993003.00465-2017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2017 |e 4 |b 02 |c 10 | ||